Risk stratification for selecting empiric antibiotherapy during and after COVID-19

aUniversity Paris-Cité, INSERM U1137, IAME, Team DeSCID, Paris

bInfections Control Unit, Avicenne Hospital, APHP, Bobigny

cMedical and Infectious Diseases Intensive Care Unit (MI2), Bichat-Claude Bernard Hospital, APHP, Paris, France

Correspondence to Jean-Francois Timsit, MD, PhD, Prof Medical and Infectious, Diseases Intensive Care Unit, AP-HP, Bichat Hospital, Paris Diderot University, 46 Rue Henri, Huchard, F-75018 Paris, France. Tel: +33 140 257 703; e-mail: [email protected]

留言 (0)

沒有登入
gif